Why Did Genmab A/S Shares Soar 13.1% Despite Mixed Analyst Signals?

Genmab A/S shares surged 13.1% in pre-market trading on May 16, 2025, driven by a mix of positive and negative signals from analysts and market trends.

Analysts at H.C. Wainwright adjusted their outlook on Genmab A/S, lowering the 12-month price target to $35 from the previous $37. This adjustment came following the company's Q1 report, which kept a Buy rating on the shares.

Despite the price target reduction, the consensus among analysts remains relatively bullish. The average target price for Genmab A/S is $30.72, with a high estimate of $45.00. Additionally, UBS lowered its target price for Genmab to DKK 2,600 from DKK 2,700, while reiterating a Buy recommendation.

MarketBeat.com data indicates that Genmab A/S has a consensus rating of "Moderate Buy" and a consensus target price of $39.17. This suggests that while there are concerns about the stock's performance, many analysts still see potential for growth.